InvestorsHub Logo
Followers 58
Posts 3929
Boards Moderated 0
Alias Born 04/23/2013

Re: dogn post# 423648

Monday, 04/29/2024 3:48:42 AM

Monday, April 29, 2024 3:48:42 AM

Post# of 425795
Lately we’ve been getting numerous studies showing that icosapent ethyl is effective and consistent in reducing MACE across a broad range of markers such as TG, LDL-c, Lp(a) and CV Risk Scoring.

This suggests to me that the current labeling for VAZKEPA/VASCEPA is too narrow and because of it’s safety profile should be initiated regardless of baseline TG’s, LDL-c, Lp(a), Risk Scores etc.

Any Doc/Cardio’s out there want to chime in?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News